



SERVATUS
Biopharmaceuticals



JUST IN

NEWS

SPORT

LIFESTYLE

COMMUNITY

JOBS

MOTORING



📷 The Servatus team at the University of the Sunshine Coast team are researching and manufacturing medicines to combat rheumatoid arthritis and other conditions. Nicolas Pichon, Renato Lemgruber, Nicolas Kong, Ben Hawthorne, Christopher de Bakker, Samantha Coulson, Kylie Ralston and Wayne Finlayson (front) Picture: Warren Lynam

Drug discovery company in

massive \$10m Coast move



by [SCOTT SAWYER](#)

25th Mar 2019 11:00 AM

Subscriber only



EXCLUSIVE: A homegrown drug discovery company is preparing a massive \$10 million move which could benefit sufferers of rheumatoid arthritis and other conditions.

Innovation Centre Sunshine Coast-based Servatus is preparing to shift slightly north to Suncoast Business Park at Quanda Road, Coolumb, to establish its long-term future.

Contracts have been placed on a 4400sqm land parcel in a deal worth just less than a million dollars, with Servatus set to establish a new

Contracts have been placed on a 4400sqm land parcel in a deal worth just less than a million dollars, with Servatus set to establish a new headquarters, alongside a joint venture partner, to create Australian Biotherapeutics.

More Stories

[Lure of a fishing line grows as uni boss confirms exit plans](#)



[Thirsty? How about a seaweed-based beer?](#)



[BREAKING: USC to expand Gympie campus for next semester](#)



Australian Biotherapeutics will manufacture high-quality, live biotherapeutics at the \$10.4 million facility for global export.

Stage One of the facility was planned to start in May, with a development application imminent.

Servatus CEO Dr Wayne Finlayson said they hoped to complete Stage One by the end of this year and then Stage Two would be rolled out over the next few years, with the entire, state-of-the-art facility to be complete within five years.

Photos

[View Photo Gallery](#)



Dr Finlayson said their joint venture partner would give them access to a broad distribution network which covered 51 countries, which they would use initially to export their active ingredients to the US for wider circulation.

Alongside those operations, Dr Finlayson said they would be actively researching and developing auto-immune treatment drugs.

"It's a good partnership for us," he said.


He said without the State Government's support, they would've had to establish their facility in the US.



① NORTH WEST PERSPECTIVE.



② ENTRY PERSPECTIVE - COMPLETE.

 IMPRESSION: Architectural drawings of the proposed new Australian Biotherapeutics headquarters in Coolom.

Picture: Contributed

Instead, they'll be employing about 25 high-paid employees, from PhD to graduate level, including a number of locals, to carry out their important work.

They targeted registered, prescription-based medicines and were focused on auto-immune drugs, initially targeting conditions like rheumatoid arthritis and psoriasis.

Instead, they'll be employing about 25 high-paid employees, from PhD to graduate level, including a number of locals, to carry out their important work.

They targeted registered, prescription-based medicines and were focused on auto-immune drugs, initially targeting conditions like rheumatoid arthritis and psoriasis.

He said they were also working on injectable and microbial biotherapeutics targeting inflammation and conditions like colitis and Crohn's disease, and they were close to carrying out human trials in the near future.

"It's an overnight success five-six years in the making," Dr Finlayson said with a laugh.